Form 4: Novavax Executive Filip Dubovsky Reports Stock Transactions
SEC Form 4 Filing
Filip Dubovsky, President of R&D at Novavax, reported the vesting and subsequent disposal of restricted stock units (RSUs) and common stock.
Summary
- On March 10, 2024, Filip Dubovsky, President of R&D at Novavax, exercised 5,376 restricted stock units (RSUs) which converted into common stock.
- Simultaneously, Dubovsky disposed of 2,597 shares of common stock at a price of $5.45 per share.
- Following these transactions, Dubovsky directly owns 66,613 shares of Novavax common stock and 5,376 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.
Key Dates
| Date | Description |
|---|---|
| 03/10/2022 | Original grant date of the restricted stock units, vesting in three annual installments. |
| 03/10/2024 | Date of the reported transactions: RSU vesting and stock disposal. |
| 03/12/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.